nodes	percent_of_prediction	percent_of_DWPC	metapath
Nebivolol—CYP2D6—Fingolimod—multiple sclerosis	0.0111	0.804	CbGbCtD
Nebivolol—Mental disorder—Cladribine—multiple sclerosis	0.0067	0.00736	CcSEcCtD
Nebivolol—Malnutrition—Cladribine—multiple sclerosis	0.00666	0.00731	CcSEcCtD
Nebivolol—Diarrhoea—Fingolimod—multiple sclerosis	0.00656	0.0072	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.00654	0.00718	CcSEcCtD
Nebivolol—Dizziness—Fingolimod—multiple sclerosis	0.00634	0.00696	CcSEcCtD
Nebivolol—Hypercholesterolaemia—Prednisone—multiple sclerosis	0.00631	0.00693	CcSEcCtD
Nebivolol—Headache—Fingolimod—multiple sclerosis	0.006	0.00659	CcSEcCtD
Nebivolol—Erectile dysfunction—Mitoxantrone—multiple sclerosis	0.00578	0.00635	CcSEcCtD
Nebivolol—Chest pain—Cladribine—multiple sclerosis	0.00567	0.00622	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00563	0.00618	CcSEcCtD
Nebivolol—Acute coronary syndrome—Mitoxantrone—multiple sclerosis	0.00552	0.00606	CcSEcCtD
Nebivolol—Myocardial infarction—Mitoxantrone—multiple sclerosis	0.00549	0.00603	CcSEcCtD
Nebivolol—Nervous system disorder—Cladribine—multiple sclerosis	0.00533	0.00585	CcSEcCtD
Nebivolol—Thrombocytopenia—Cladribine—multiple sclerosis	0.00532	0.00584	CcSEcCtD
Nebivolol—Skin disorder—Cladribine—multiple sclerosis	0.00528	0.00579	CcSEcCtD
Nebivolol—Bradycardia—Mitoxantrone—multiple sclerosis	0.00512	0.00562	CcSEcCtD
Nebivolol—Insomnia—Cladribine—multiple sclerosis	0.00491	0.0054	CcSEcCtD
Nebivolol—Paraesthesia—Cladribine—multiple sclerosis	0.00488	0.00536	CcSEcCtD
Nebivolol—Dyspnoea—Cladribine—multiple sclerosis	0.00484	0.00532	CcSEcCtD
Nebivolol—Somnolence—Cladribine—multiple sclerosis	0.00483	0.0053	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00469	0.00515	CcSEcCtD
Nebivolol—Fatigue—Cladribine—multiple sclerosis	0.00468	0.00514	CcSEcCtD
Nebivolol—Bronchospasm—Methylprednisolone—multiple sclerosis	0.00465	0.00511	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00458	0.00502	CcSEcCtD
Nebivolol—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.00453	0.00497	CcSEcCtD
Nebivolol—Myocardial infarction—Prednisolone—multiple sclerosis	0.0045	0.00494	CcSEcCtD
Nebivolol—Gastrointestinal pain—Cladribine—multiple sclerosis	0.00444	0.00488	CcSEcCtD
Nebivolol—Thrombocytopenia—Azathioprine—multiple sclerosis	0.00432	0.00475	CcSEcCtD
Nebivolol—Urticaria—Cladribine—multiple sclerosis	0.00432	0.00474	CcSEcCtD
Nebivolol—Abdominal pain—Cladribine—multiple sclerosis	0.00429	0.00472	CcSEcCtD
Nebivolol—Skin disorder—Azathioprine—multiple sclerosis	0.00429	0.00471	CcSEcCtD
Nebivolol—Bradycardia—Prednisolone—multiple sclerosis	0.0042	0.00461	CcSEcCtD
Nebivolol—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.00416	0.00457	CcSEcCtD
Nebivolol—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.00415	0.00456	CcSEcCtD
Nebivolol—Myocardial infarction—Triamcinolone—multiple sclerosis	0.00414	0.00455	CcSEcCtD
Nebivolol—Myocardial infarction—Methylprednisolone—multiple sclerosis	0.00413	0.00454	CcSEcCtD
Nebivolol—Hypersensitivity—Cladribine—multiple sclerosis	0.004	0.00439	CcSEcCtD
Nebivolol—Renal failure acute—Methotrexate—multiple sclerosis	0.00392	0.00431	CcSEcCtD
Nebivolol—Asthenia—Cladribine—multiple sclerosis	0.0039	0.00428	CcSEcCtD
Nebivolol—Bradycardia—Triamcinolone—multiple sclerosis	0.00386	0.00424	CcSEcCtD
Nebivolol—Bradycardia—Methylprednisolone—multiple sclerosis	0.00385	0.00423	CcSEcCtD
Nebivolol—Pruritus—Cladribine—multiple sclerosis	0.00384	0.00422	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00381	0.00419	CcSEcCtD
Nebivolol—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.00378	0.00415	CcSEcCtD
Nebivolol—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.00378	0.00415	CcSEcCtD
Nebivolol—Myocardial infarction—Dexamethasone—multiple sclerosis	0.00376	0.00413	CcSEcCtD
Nebivolol—Myocardial infarction—Betamethasone—multiple sclerosis	0.00376	0.00413	CcSEcCtD
Nebivolol—Chest pain—Mitoxantrone—multiple sclerosis	0.00372	0.00409	CcSEcCtD
Nebivolol—Diarrhoea—Cladribine—multiple sclerosis	0.00372	0.00408	CcSEcCtD
Nebivolol—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.00361	0.00397	CcSEcCtD
Nebivolol—Dizziness—Cladribine—multiple sclerosis	0.00359	0.00394	CcSEcCtD
Nebivolol—Shock—Mitoxantrone—multiple sclerosis	0.00351	0.00386	CcSEcCtD
Nebivolol—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.00351	0.00386	CcSEcCtD
Nebivolol—Bradycardia—Dexamethasone—multiple sclerosis	0.0035	0.00385	CcSEcCtD
Nebivolol—Bradycardia—Betamethasone—multiple sclerosis	0.0035	0.00385	CcSEcCtD
Nebivolol—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.0035	0.00384	CcSEcCtD
Nebivolol—Abdominal pain—Azathioprine—multiple sclerosis	0.00349	0.00383	CcSEcCtD
Nebivolol—Skin disorder—Mitoxantrone—multiple sclerosis	0.00347	0.00381	CcSEcCtD
Nebivolol—Vomiting—Cladribine—multiple sclerosis	0.00345	0.00379	CcSEcCtD
Nebivolol—Erectile dysfunction—Prednisone—multiple sclerosis	0.00345	0.00379	CcSEcCtD
Nebivolol—Rash—Cladribine—multiple sclerosis	0.00343	0.00376	CcSEcCtD
Nebivolol—Dermatitis—Cladribine—multiple sclerosis	0.00342	0.00376	CcSEcCtD
Nebivolol—Headache—Cladribine—multiple sclerosis	0.0034	0.00374	CcSEcCtD
Nebivolol—Mental disorder—Methylprednisolone—multiple sclerosis	0.00331	0.00364	CcSEcCtD
Nebivolol—Malnutrition—Methylprednisolone—multiple sclerosis	0.00329	0.00362	CcSEcCtD
Nebivolol—Acute coronary syndrome—Prednisone—multiple sclerosis	0.00329	0.00361	CcSEcCtD
Nebivolol—Angioedema—Prednisolone—multiple sclerosis	0.00328	0.0036	CcSEcCtD
Nebivolol—Myocardial infarction—Prednisone—multiple sclerosis	0.00327	0.00359	CcSEcCtD
Nebivolol—Hypersensitivity—Azathioprine—multiple sclerosis	0.00325	0.00357	CcSEcCtD
Nebivolol—Nausea—Cladribine—multiple sclerosis	0.00323	0.00354	CcSEcCtD
Nebivolol—Vertigo—Prednisolone—multiple sclerosis	0.00323	0.00354	CcSEcCtD
Nebivolol—Syncope—Prednisolone—multiple sclerosis	0.00322	0.00353	CcSEcCtD
Nebivolol—Paraesthesia—Mitoxantrone—multiple sclerosis	0.00321	0.00352	CcSEcCtD
Nebivolol—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00318	0.0035	CcSEcCtD
Nebivolol—Somnolence—Mitoxantrone—multiple sclerosis	0.00317	0.00349	CcSEcCtD
Nebivolol—Loss of consciousness—Prednisolone—multiple sclerosis	0.00315	0.00346	CcSEcCtD
Nebivolol—Fatigue—Mitoxantrone—multiple sclerosis	0.00308	0.00338	CcSEcCtD
Nebivolol—Bradycardia—Prednisone—multiple sclerosis	0.00305	0.00335	CcSEcCtD
Nebivolol—Diarrhoea—Azathioprine—multiple sclerosis	0.00302	0.00332	CcSEcCtD
Nebivolol—Angioedema—Triamcinolone—multiple sclerosis	0.00302	0.00331	CcSEcCtD
Nebivolol—Angioedema—Methylprednisolone—multiple sclerosis	0.00301	0.0033	CcSEcCtD
Nebivolol—Vertigo—Triamcinolone—multiple sclerosis	0.00297	0.00326	CcSEcCtD
Nebivolol—Syncope—Triamcinolone—multiple sclerosis	0.00296	0.00325	CcSEcCtD
Nebivolol—Vertigo—Methylprednisolone—multiple sclerosis	0.00296	0.00325	CcSEcCtD
Nebivolol—Syncope—Methylprednisolone—multiple sclerosis	0.00295	0.00324	CcSEcCtD
Nebivolol—Dizziness—Azathioprine—multiple sclerosis	0.00292	0.00321	CcSEcCtD
Nebivolol—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00292	0.00321	CcSEcCtD
Nebivolol—Loss of consciousness—Triamcinolone—multiple sclerosis	0.0029	0.00319	CcSEcCtD
Nebivolol—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.00289	0.00318	CcSEcCtD
Nebivolol—Shock—Prednisolone—multiple sclerosis	0.00288	0.00316	CcSEcCtD
Nebivolol—Erectile dysfunction—Methotrexate—multiple sclerosis	0.00288	0.00316	CcSEcCtD
Nebivolol—Urticaria—Mitoxantrone—multiple sclerosis	0.00284	0.00311	CcSEcCtD
Nebivolol—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00282	0.0031	CcSEcCtD
Nebivolol—Vomiting—Azathioprine—multiple sclerosis	0.00281	0.00308	CcSEcCtD
Nebivolol—Rash—Azathioprine—multiple sclerosis	0.00279	0.00306	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00278	0.00306	CcSEcCtD
Nebivolol—Dermatitis—Azathioprine—multiple sclerosis	0.00278	0.00306	CcSEcCtD
Nebivolol—Headache—Azathioprine—multiple sclerosis	0.00277	0.00304	CcSEcCtD
Nebivolol—Angioedema—Betamethasone—multiple sclerosis	0.00274	0.00301	CcSEcCtD
Nebivolol—Angioedema—Dexamethasone—multiple sclerosis	0.00274	0.00301	CcSEcCtD
Nebivolol—CYP2D6—Dexamethasone—multiple sclerosis	0.0027	0.196	CbGbCtD
Nebivolol—Vertigo—Dexamethasone—multiple sclerosis	0.00269	0.00295	CcSEcCtD
Nebivolol—Vertigo—Betamethasone—multiple sclerosis	0.00269	0.00295	CcSEcCtD
Nebivolol—Syncope—Betamethasone—multiple sclerosis	0.00269	0.00295	CcSEcCtD
Nebivolol—Syncope—Dexamethasone—multiple sclerosis	0.00269	0.00295	CcSEcCtD
Nebivolol—Shock—Triamcinolone—multiple sclerosis	0.00265	0.00291	CcSEcCtD
Nebivolol—Insomnia—Prednisolone—multiple sclerosis	0.00265	0.00291	CcSEcCtD
Nebivolol—Shock—Methylprednisolone—multiple sclerosis	0.00264	0.0029	CcSEcCtD
Nebivolol—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00264	0.00289	CcSEcCtD
Nebivolol—Loss of consciousness—Betamethasone—multiple sclerosis	0.00263	0.00289	CcSEcCtD
Nebivolol—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00263	0.00289	CcSEcCtD
Nebivolol—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00263	0.00289	CcSEcCtD
Nebivolol—Paraesthesia—Prednisolone—multiple sclerosis	0.00263	0.00289	CcSEcCtD
Nebivolol—Mental disorder—Prednisone—multiple sclerosis	0.00263	0.00288	CcSEcCtD
Nebivolol—Nausea—Azathioprine—multiple sclerosis	0.00262	0.00288	CcSEcCtD
Nebivolol—Skin disorder—Methylprednisolone—multiple sclerosis	0.00261	0.00287	CcSEcCtD
Nebivolol—Malnutrition—Prednisone—multiple sclerosis	0.00261	0.00286	CcSEcCtD
Nebivolol—Asthenia—Mitoxantrone—multiple sclerosis	0.00256	0.00281	CcSEcCtD
Nebivolol—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00244	0.00268	CcSEcCtD
Nebivolol—Insomnia—Triamcinolone—multiple sclerosis	0.00244	0.00268	CcSEcCtD
Nebivolol—Insomnia—Methylprednisolone—multiple sclerosis	0.00243	0.00267	CcSEcCtD
Nebivolol—Paraesthesia—Triamcinolone—multiple sclerosis	0.00242	0.00266	CcSEcCtD
Nebivolol—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00241	0.00265	CcSEcCtD
Nebivolol—Shock—Dexamethasone—multiple sclerosis	0.0024	0.00264	CcSEcCtD
Nebivolol—Shock—Betamethasone—multiple sclerosis	0.0024	0.00264	CcSEcCtD
Nebivolol—Dyspnoea—Triamcinolone—multiple sclerosis	0.0024	0.00264	CcSEcCtD
Nebivolol—Nervous system disorder—Dexamethasone—multiple sclerosis	0.0024	0.00263	CcSEcCtD
Nebivolol—Nervous system disorder—Betamethasone—multiple sclerosis	0.0024	0.00263	CcSEcCtD
Nebivolol—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.00239	0.00263	CcSEcCtD
Nebivolol—Thrombocytopenia—Betamethasone—multiple sclerosis	0.00239	0.00263	CcSEcCtD
Nebivolol—Angioedema—Prednisone—multiple sclerosis	0.00238	0.00262	CcSEcCtD
Nebivolol—Vertigo—Prednisone—multiple sclerosis	0.00234	0.00257	CcSEcCtD
Nebivolol—Syncope—Prednisone—multiple sclerosis	0.00234	0.00257	CcSEcCtD
Nebivolol—Urticaria—Prednisolone—multiple sclerosis	0.00233	0.00256	CcSEcCtD
Nebivolol—Cardiac disorder—Methotrexate—multiple sclerosis	0.00232	0.00255	CcSEcCtD
Nebivolol—Fatigue—Triamcinolone—multiple sclerosis	0.00232	0.00255	CcSEcCtD
Nebivolol—Fatigue—Methylprednisolone—multiple sclerosis	0.00232	0.00254	CcSEcCtD
Nebivolol—Loss of consciousness—Prednisone—multiple sclerosis	0.00229	0.00252	CcSEcCtD
Nebivolol—Vomiting—Mitoxantrone—multiple sclerosis	0.00227	0.00249	CcSEcCtD
Nebivolol—Rash—Mitoxantrone—multiple sclerosis	0.00225	0.00247	CcSEcCtD
Nebivolol—Dermatitis—Mitoxantrone—multiple sclerosis	0.00225	0.00247	CcSEcCtD
Nebivolol—Headache—Mitoxantrone—multiple sclerosis	0.00224	0.00246	CcSEcCtD
Nebivolol—Insomnia—Dexamethasone—multiple sclerosis	0.00221	0.00243	CcSEcCtD
Nebivolol—Insomnia—Betamethasone—multiple sclerosis	0.00221	0.00243	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00221	0.00242	CcSEcCtD
Nebivolol—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.0022	0.00241	CcSEcCtD
Nebivolol—Paraesthesia—Dexamethasone—multiple sclerosis	0.0022	0.00241	CcSEcCtD
Nebivolol—Paraesthesia—Betamethasone—multiple sclerosis	0.0022	0.00241	CcSEcCtD
Nebivolol—Mental disorder—Methotrexate—multiple sclerosis	0.00219	0.00241	CcSEcCtD
Nebivolol—Malnutrition—Methotrexate—multiple sclerosis	0.00218	0.00239	CcSEcCtD
Nebivolol—Hypersensitivity—Prednisolone—multiple sclerosis	0.00216	0.00237	CcSEcCtD
Nebivolol—Urticaria—Triamcinolone—multiple sclerosis	0.00214	0.00235	CcSEcCtD
Nebivolol—Urticaria—Methylprednisolone—multiple sclerosis	0.00214	0.00234	CcSEcCtD
Nebivolol—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00212	0.00233	CcSEcCtD
Nebivolol—Nausea—Mitoxantrone—multiple sclerosis	0.00212	0.00233	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00211	0.00232	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00211	0.00232	CcSEcCtD
Nebivolol—Fatigue—Dexamethasone—multiple sclerosis	0.00211	0.00231	CcSEcCtD
Nebivolol—Fatigue—Betamethasone—multiple sclerosis	0.00211	0.00231	CcSEcCtD
Nebivolol—Shock—Prednisone—multiple sclerosis	0.00209	0.0023	CcSEcCtD
Nebivolol—Nervous system disorder—Prednisone—multiple sclerosis	0.00209	0.00229	CcSEcCtD
Nebivolol—Skin disorder—Prednisone—multiple sclerosis	0.00207	0.00227	CcSEcCtD
Nebivolol—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.002	0.00219	CcSEcCtD
Nebivolol—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.002	0.00219	CcSEcCtD
Nebivolol—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00198	0.00218	CcSEcCtD
Nebivolol—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00198	0.00217	CcSEcCtD
Nebivolol—Vertigo—Methotrexate—multiple sclerosis	0.00196	0.00215	CcSEcCtD
Nebivolol—Urticaria—Betamethasone—multiple sclerosis	0.00194	0.00213	CcSEcCtD
Nebivolol—Urticaria—Dexamethasone—multiple sclerosis	0.00194	0.00213	CcSEcCtD
Nebivolol—Dizziness—Prednisolone—multiple sclerosis	0.00194	0.00213	CcSEcCtD
Nebivolol—Asthenia—Triamcinolone—multiple sclerosis	0.00193	0.00212	CcSEcCtD
Nebivolol—Abdominal pain—Dexamethasone—multiple sclerosis	0.00193	0.00212	CcSEcCtD
Nebivolol—Abdominal pain—Betamethasone—multiple sclerosis	0.00193	0.00212	CcSEcCtD
Nebivolol—Asthenia—Methylprednisolone—multiple sclerosis	0.00193	0.00212	CcSEcCtD
Nebivolol—Insomnia—Prednisone—multiple sclerosis	0.00193	0.00211	CcSEcCtD
Nebivolol—Paraesthesia—Prednisone—multiple sclerosis	0.00191	0.0021	CcSEcCtD
Nebivolol—Pruritus—Triamcinolone—multiple sclerosis	0.00191	0.00209	CcSEcCtD
Nebivolol—Pruritus—Methylprednisolone—multiple sclerosis	0.0019	0.00209	CcSEcCtD
Nebivolol—Chest pain—Methotrexate—multiple sclerosis	0.00186	0.00204	CcSEcCtD
Nebivolol—Rash—Prednisolone—multiple sclerosis	0.00185	0.00203	CcSEcCtD
Nebivolol—Dermatitis—Prednisolone—multiple sclerosis	0.00185	0.00203	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00184	0.00202	CcSEcCtD
Nebivolol—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00184	0.00202	CcSEcCtD
Nebivolol—Fatigue—Prednisone—multiple sclerosis	0.00184	0.00202	CcSEcCtD
Nebivolol—Headache—Prednisolone—multiple sclerosis	0.00184	0.00202	CcSEcCtD
Nebivolol—Dizziness—Triamcinolone—multiple sclerosis	0.00178	0.00196	CcSEcCtD
Nebivolol—Dizziness—Methylprednisolone—multiple sclerosis	0.00178	0.00195	CcSEcCtD
Nebivolol—Asthenia—Dexamethasone—multiple sclerosis	0.00175	0.00193	CcSEcCtD
Nebivolol—Asthenia—Betamethasone—multiple sclerosis	0.00175	0.00193	CcSEcCtD
Nebivolol—Nervous system disorder—Methotrexate—multiple sclerosis	0.00174	0.00192	CcSEcCtD
Nebivolol—Thrombocytopenia—Methotrexate—multiple sclerosis	0.00174	0.00191	CcSEcCtD
Nebivolol—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00174	0.00191	CcSEcCtD
Nebivolol—Nausea—Prednisolone—multiple sclerosis	0.00174	0.00191	CcSEcCtD
Nebivolol—Pruritus—Dexamethasone—multiple sclerosis	0.00173	0.0019	CcSEcCtD
Nebivolol—Pruritus—Betamethasone—multiple sclerosis	0.00173	0.0019	CcSEcCtD
Nebivolol—Skin disorder—Methotrexate—multiple sclerosis	0.00173	0.0019	CcSEcCtD
Nebivolol—Vomiting—Triamcinolone—multiple sclerosis	0.00171	0.00188	CcSEcCtD
Nebivolol—Vomiting—Methylprednisolone—multiple sclerosis	0.00171	0.00188	CcSEcCtD
Nebivolol—Rash—Triamcinolone—multiple sclerosis	0.0017	0.00187	CcSEcCtD
Nebivolol—Dermatitis—Triamcinolone—multiple sclerosis	0.0017	0.00186	CcSEcCtD
Nebivolol—Rash—Methylprednisolone—multiple sclerosis	0.00169	0.00186	CcSEcCtD
Nebivolol—Dermatitis—Methylprednisolone—multiple sclerosis	0.00169	0.00186	CcSEcCtD
Nebivolol—Urticaria—Prednisone—multiple sclerosis	0.00169	0.00186	CcSEcCtD
Nebivolol—Headache—Triamcinolone—multiple sclerosis	0.00169	0.00185	CcSEcCtD
Nebivolol—Headache—Methylprednisolone—multiple sclerosis	0.00168	0.00185	CcSEcCtD
Nebivolol—Abdominal pain—Prednisone—multiple sclerosis	0.00168	0.00185	CcSEcCtD
Nebivolol—Diarrhoea—Dexamethasone—multiple sclerosis	0.00167	0.00184	CcSEcCtD
Nebivolol—Diarrhoea—Betamethasone—multiple sclerosis	0.00167	0.00184	CcSEcCtD
Nebivolol—Dizziness—Betamethasone—multiple sclerosis	0.00162	0.00177	CcSEcCtD
Nebivolol—Dizziness—Dexamethasone—multiple sclerosis	0.00162	0.00177	CcSEcCtD
Nebivolol—Insomnia—Methotrexate—multiple sclerosis	0.00161	0.00177	CcSEcCtD
Nebivolol—Nausea—Triamcinolone—multiple sclerosis	0.0016	0.00176	CcSEcCtD
Nebivolol—Paraesthesia—Methotrexate—multiple sclerosis	0.0016	0.00175	CcSEcCtD
Nebivolol—Nausea—Methylprednisolone—multiple sclerosis	0.0016	0.00175	CcSEcCtD
Nebivolol—Dyspnoea—Methotrexate—multiple sclerosis	0.00159	0.00174	CcSEcCtD
Nebivolol—Somnolence—Methotrexate—multiple sclerosis	0.00158	0.00174	CcSEcCtD
Nebivolol—Hypersensitivity—Prednisone—multiple sclerosis	0.00157	0.00172	CcSEcCtD
Nebivolol—Vomiting—Betamethasone—multiple sclerosis	0.00155	0.00171	CcSEcCtD
Nebivolol—Vomiting—Dexamethasone—multiple sclerosis	0.00155	0.00171	CcSEcCtD
Nebivolol—Rash—Betamethasone—multiple sclerosis	0.00154	0.00169	CcSEcCtD
Nebivolol—Rash—Dexamethasone—multiple sclerosis	0.00154	0.00169	CcSEcCtD
Nebivolol—Dermatitis—Betamethasone—multiple sclerosis	0.00154	0.00169	CcSEcCtD
Nebivolol—Dermatitis—Dexamethasone—multiple sclerosis	0.00154	0.00169	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00154	0.00169	CcSEcCtD
Nebivolol—Fatigue—Methotrexate—multiple sclerosis	0.00153	0.00168	CcSEcCtD
Nebivolol—Headache—Betamethasone—multiple sclerosis	0.00153	0.00168	CcSEcCtD
Nebivolol—Headache—Dexamethasone—multiple sclerosis	0.00153	0.00168	CcSEcCtD
Nebivolol—Asthenia—Prednisone—multiple sclerosis	0.00153	0.00168	CcSEcCtD
Nebivolol—Pruritus—Prednisone—multiple sclerosis	0.00151	0.00165	CcSEcCtD
Nebivolol—Diarrhoea—Prednisone—multiple sclerosis	0.00146	0.0016	CcSEcCtD
Nebivolol—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.00145	0.0016	CcSEcCtD
Nebivolol—Nausea—Betamethasone—multiple sclerosis	0.00145	0.00159	CcSEcCtD
Nebivolol—Nausea—Dexamethasone—multiple sclerosis	0.00145	0.00159	CcSEcCtD
Nebivolol—Urticaria—Methotrexate—multiple sclerosis	0.00141	0.00155	CcSEcCtD
Nebivolol—Dizziness—Prednisone—multiple sclerosis	0.00141	0.00155	CcSEcCtD
Nebivolol—Abdominal pain—Methotrexate—multiple sclerosis	0.00141	0.00154	CcSEcCtD
Nebivolol—Vomiting—Prednisone—multiple sclerosis	0.00135	0.00149	CcSEcCtD
Nebivolol—Rash—Prednisone—multiple sclerosis	0.00134	0.00147	CcSEcCtD
Nebivolol—Dermatitis—Prednisone—multiple sclerosis	0.00134	0.00147	CcSEcCtD
Nebivolol—Headache—Prednisone—multiple sclerosis	0.00133	0.00146	CcSEcCtD
Nebivolol—Hypersensitivity—Methotrexate—multiple sclerosis	0.00131	0.00144	CcSEcCtD
Nebivolol—Asthenia—Methotrexate—multiple sclerosis	0.00128	0.0014	CcSEcCtD
Nebivolol—Nausea—Prednisone—multiple sclerosis	0.00126	0.00139	CcSEcCtD
Nebivolol—Pruritus—Methotrexate—multiple sclerosis	0.00126	0.00138	CcSEcCtD
Nebivolol—Diarrhoea—Methotrexate—multiple sclerosis	0.00122	0.00134	CcSEcCtD
Nebivolol—Dizziness—Methotrexate—multiple sclerosis	0.00118	0.00129	CcSEcCtD
Nebivolol—Vomiting—Methotrexate—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Nebivolol—Rash—Methotrexate—multiple sclerosis	0.00112	0.00123	CcSEcCtD
Nebivolol—Dermatitis—Methotrexate—multiple sclerosis	0.00112	0.00123	CcSEcCtD
Nebivolol—Headache—Methotrexate—multiple sclerosis	0.00111	0.00122	CcSEcCtD
Nebivolol—Nausea—Methotrexate—multiple sclerosis	0.00106	0.00116	CcSEcCtD
Nebivolol—ADRB2—GPCR ligand binding—CXCR3—multiple sclerosis	0.000212	0.0028	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—CCR2—multiple sclerosis	0.00021	0.00279	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—RGS1—multiple sclerosis	0.000208	0.00276	CbGpPWpGaD
Nebivolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000208	0.00275	CbGpPWpGaD
Nebivolol—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000207	0.00274	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CXCR3—multiple sclerosis	0.000207	0.00274	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—CCR2—multiple sclerosis	0.000206	0.00273	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—RGS1—multiple sclerosis	0.000204	0.0027	CbGpPWpGaD
Nebivolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000203	0.00269	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000202	0.00267	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CCR2—multiple sclerosis	0.000201	0.00267	CbGpPWpGaD
Nebivolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000199	0.00263	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000198	0.00262	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—GPR65—multiple sclerosis	0.000197	0.00261	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—CNR1—multiple sclerosis	0.000194	0.00257	CbGpPWpGaD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000193	0.00256	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—RGS1—multiple sclerosis	0.000193	0.00256	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—GPR65—multiple sclerosis	0.000193	0.00256	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—CNR1—multiple sclerosis	0.00019	0.00252	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—RGS1—multiple sclerosis	0.000189	0.0025	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000189	0.0025	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CNR1—multiple sclerosis	0.000186	0.00246	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—RGS1—multiple sclerosis	0.000185	0.00245	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000185	0.00244	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000185	0.00244	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—GPR65—multiple sclerosis	0.000183	0.00243	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CXCL13—multiple sclerosis	0.00018	0.00239	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CCR1—multiple sclerosis	0.00018	0.00239	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—GPR65—multiple sclerosis	0.000179	0.00237	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000178	0.00236	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—LINGO1—multiple sclerosis	0.000177	0.00235	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CCR1—multiple sclerosis	0.000176	0.00234	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000176	0.00234	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—GPR65—multiple sclerosis	0.000175	0.00232	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000175	0.00232	CbGpPWpGaD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000174	0.00231	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—LINGO1—multiple sclerosis	0.000173	0.0023	CbGpPWpGaD
Nebivolol—HTR1A—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000172	0.00228	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—CXCL10—multiple sclerosis	0.000171	0.00227	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.00017	0.00226	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—LINGO1—multiple sclerosis	0.000169	0.00225	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000168	0.00222	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CCR1—multiple sclerosis	0.000168	0.00222	CbGpPWpGaD
Nebivolol—HTR1A—G alpha (i) signalling events—POMC—multiple sclerosis	0.000167	0.00222	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CXCL10—multiple sclerosis	0.000167	0.00222	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CXCL13—multiple sclerosis	0.000164	0.00217	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CCR1—multiple sclerosis	0.000164	0.00217	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CCR1—multiple sclerosis	0.00016	0.00212	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CXCL13—multiple sclerosis	0.00016	0.00212	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TAGAP—multiple sclerosis	0.000154	0.00204	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—CCL5—multiple sclerosis	0.00015	0.00199	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TAGAP—multiple sclerosis	0.00015	0.00199	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—CCL5—multiple sclerosis	0.000147	0.00195	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TAGAP—multiple sclerosis	0.000147	0.00195	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CCL5—multiple sclerosis	0.000144	0.00191	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000139	0.00184	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000136	0.0018	CbGpPWpGaD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000136	0.0018	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—CCR5—multiple sclerosis	0.000136	0.0018	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—S1PR1—multiple sclerosis	0.000134	0.00178	CbGpPWpGaD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000133	0.00176	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000133	0.00176	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—CCR5—multiple sclerosis	0.000133	0.00176	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—S1PR1—multiple sclerosis	0.000131	0.00174	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—GPC5—multiple sclerosis	0.000131	0.00173	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.00013	0.00173	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CCR5—multiple sclerosis	0.00013	0.00172	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—S1PR1—multiple sclerosis	0.000128	0.0017	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—GPC5—multiple sclerosis	0.000128	0.00169	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000127	0.00168	CbGpPWpGaD
Nebivolol—HTR1A—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.000125	0.00166	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—GPC5—multiple sclerosis	0.000125	0.00166	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000124	0.00164	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000122	0.00162	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000121	0.0016	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CXCR3—multiple sclerosis	0.00012	0.00158	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CCL3—multiple sclerosis	0.000119	0.00158	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000119	0.00158	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—SRM—multiple sclerosis	0.000119	0.00157	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000117	0.00155	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CCL3—multiple sclerosis	0.000117	0.00155	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CCR2—multiple sclerosis	0.000116	0.00154	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000115	0.00152	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CCL3—multiple sclerosis	0.000114	0.00151	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—RGS1—multiple sclerosis	0.000114	0.00151	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CCR2—multiple sclerosis	0.000114	0.00151	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—PTGER4—multiple sclerosis	0.000112	0.00149	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—RGS1—multiple sclerosis	0.000112	0.00148	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CXCR3—multiple sclerosis	0.000111	0.00147	CbGpPWpGaD
Nebivolol—CYP2D6—Biological oxidations—POMC—multiple sclerosis	0.00011	0.00146	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PTGER4—multiple sclerosis	0.00011	0.00146	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CNR1—multiple sclerosis	0.00011	0.00145	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—RGS1—multiple sclerosis	0.000109	0.00145	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CXCR3—multiple sclerosis	0.000109	0.00144	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—GPR65—multiple sclerosis	0.000108	0.00143	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CCR2—multiple sclerosis	0.000108	0.00143	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CNR1—multiple sclerosis	0.000107	0.00142	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CXCR3—multiple sclerosis	0.000106	0.00141	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—POMC—multiple sclerosis	0.000106	0.0014	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—GPR65—multiple sclerosis	0.000106	0.0014	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CCR2—multiple sclerosis	0.000106	0.0014	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CNR1—multiple sclerosis	0.000105	0.00139	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—CCL2—multiple sclerosis	0.000104	0.00137	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—POMC—multiple sclerosis	0.000104	0.00137	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—GPR65—multiple sclerosis	0.000104	0.00137	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CCR2—multiple sclerosis	0.000103	0.00137	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—CCL2—multiple sclerosis	0.000101	0.00134	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—POMC—multiple sclerosis	0.000101	0.00134	CbGpPWpGaD
Nebivolol—HTR1A—SIDS Susceptibility Pathways—IL6—multiple sclerosis	0.000101	0.00134	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CNR1—multiple sclerosis	9.96e-05	0.00132	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CCL2—multiple sclerosis	9.92e-05	0.00131	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CXCL13—multiple sclerosis	9.9e-05	0.00131	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCR1—multiple sclerosis	9.9e-05	0.00131	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CXCL10—multiple sclerosis	9.88e-05	0.00131	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CNR1—multiple sclerosis	9.75e-05	0.00129	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CXCL13—multiple sclerosis	9.68e-05	0.00128	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCR1—multiple sclerosis	9.68e-05	0.00128	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CXCL10—multiple sclerosis	9.66e-05	0.00128	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CNR1—multiple sclerosis	9.53e-05	0.00126	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCR1—multiple sclerosis	9.47e-05	0.00125	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CXCL13—multiple sclerosis	9.47e-05	0.00125	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CXCL10—multiple sclerosis	9.45e-05	0.00125	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CXCL10—multiple sclerosis	8.97e-05	0.00119	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CXCL10—multiple sclerosis	8.78e-05	0.00116	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CXCL10—multiple sclerosis	8.58e-05	0.00114	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CCL5—multiple sclerosis	8.5e-05	0.00113	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	8.37e-05	0.00111	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	8.37e-05	0.00111	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CCL5—multiple sclerosis	8.32e-05	0.0011	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CCL5—multiple sclerosis	8.13e-05	0.00108	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CCL5—multiple sclerosis	7.72e-05	0.00102	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CCR5—multiple sclerosis	7.66e-05	0.00102	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GPC5—multiple sclerosis	7.65e-05	0.00101	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CCL5—multiple sclerosis	7.55e-05	0.001	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—IL2RA—multiple sclerosis	7.55e-05	0.001	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CCR5—multiple sclerosis	7.49e-05	0.000993	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CCL5—multiple sclerosis	7.39e-05	0.000979	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—IL2RA—multiple sclerosis	7.39e-05	0.000979	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CCR5—multiple sclerosis	7.33e-05	0.000971	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—IL2RA—multiple sclerosis	7.22e-05	0.000957	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCL3—multiple sclerosis	7.05e-05	0.000934	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CCR5—multiple sclerosis	6.96e-05	0.000922	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCL3—multiple sclerosis	6.9e-05	0.000914	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—IL2RA—multiple sclerosis	6.86e-05	0.000908	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CCR5—multiple sclerosis	6.81e-05	0.000902	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PTGER4—multiple sclerosis	6.79e-05	0.000899	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCL3—multiple sclerosis	6.75e-05	0.000894	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—IL2RA—multiple sclerosis	6.71e-05	0.000889	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PGR—multiple sclerosis	6.69e-05	0.000886	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CCR5—multiple sclerosis	6.65e-05	0.000882	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PTGER4—multiple sclerosis	6.64e-05	0.00088	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—IL2RA—multiple sclerosis	6.56e-05	0.000869	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CXCR3—multiple sclerosis	6.56e-05	0.000869	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PGR—multiple sclerosis	6.54e-05	0.000866	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CD28—multiple sclerosis	6.5e-05	0.000861	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PTGER4—multiple sclerosis	6.49e-05	0.00086	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CXCR3—multiple sclerosis	6.41e-05	0.00085	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PGR—multiple sclerosis	6.4e-05	0.000847	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCR2—multiple sclerosis	6.38e-05	0.000845	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CD28—multiple sclerosis	6.35e-05	0.000842	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—RRM1—multiple sclerosis	6.34e-05	0.00084	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CXCR3—multiple sclerosis	6.27e-05	0.000831	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCR2—multiple sclerosis	6.24e-05	0.000827	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CD28—multiple sclerosis	6.21e-05	0.000823	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCR2—multiple sclerosis	6.1e-05	0.000808	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—POMC—multiple sclerosis	5.99e-05	0.000793	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CNR1—multiple sclerosis	5.89e-05	0.00078	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—POMC—multiple sclerosis	5.86e-05	0.000776	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CNR1—multiple sclerosis	5.76e-05	0.000763	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—POMC—multiple sclerosis	5.73e-05	0.000759	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CNR1—multiple sclerosis	5.63e-05	0.000746	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—POMC—multiple sclerosis	5.44e-05	0.00072	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CCL2—multiple sclerosis	5.32e-05	0.000705	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—POMC—multiple sclerosis	5.32e-05	0.000705	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CXCL10—multiple sclerosis	5.3e-05	0.000702	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CCL2—multiple sclerosis	5.2e-05	0.00069	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—POMC—multiple sclerosis	5.2e-05	0.000689	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CXCL10—multiple sclerosis	5.18e-05	0.000687	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CCL2—multiple sclerosis	5.09e-05	0.000674	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CXCL10—multiple sclerosis	5.07e-05	0.000672	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—TYK2—multiple sclerosis	4.83e-05	0.00064	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—TYK2—multiple sclerosis	4.73e-05	0.000626	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CD86—multiple sclerosis	4.63e-05	0.000614	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—TYK2—multiple sclerosis	4.62e-05	0.000612	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCL5—multiple sclerosis	4.56e-05	0.000604	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CD86—multiple sclerosis	4.53e-05	0.000601	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCL5—multiple sclerosis	4.46e-05	0.000591	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CD86—multiple sclerosis	4.43e-05	0.000587	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—IL2—multiple sclerosis	4.43e-05	0.000586	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCL5—multiple sclerosis	4.36e-05	0.000578	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—IL2—multiple sclerosis	4.33e-05	0.000574	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—IL2—multiple sclerosis	4.23e-05	0.000561	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—SPP1—multiple sclerosis	4.23e-05	0.00056	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—SPP1—multiple sclerosis	4.13e-05	0.000548	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCR5—multiple sclerosis	4.11e-05	0.000545	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL2RA—multiple sclerosis	4.05e-05	0.000537	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—SPP1—multiple sclerosis	4.04e-05	0.000535	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCR5—multiple sclerosis	4.02e-05	0.000533	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—IL2—multiple sclerosis	4.02e-05	0.000533	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL2RA—multiple sclerosis	3.96e-05	0.000525	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—IL2—multiple sclerosis	3.93e-05	0.000521	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCR5—multiple sclerosis	3.93e-05	0.000521	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL2RA—multiple sclerosis	3.87e-05	0.000513	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—IL2—multiple sclerosis	3.85e-05	0.000509	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—APOE—multiple sclerosis	3.74e-05	0.000495	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—APOE—multiple sclerosis	3.66e-05	0.000485	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—BCHE—multiple sclerosis	3.64e-05	0.000482	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—APOE—multiple sclerosis	3.58e-05	0.000474	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CD80—multiple sclerosis	3.38e-05	0.000448	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CD80—multiple sclerosis	3.31e-05	0.000438	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CD80—multiple sclerosis	3.23e-05	0.000428	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—POMC—multiple sclerosis	3.21e-05	0.000426	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCL2—multiple sclerosis	3.14e-05	0.000416	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—POMC—multiple sclerosis	3.14e-05	0.000416	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—MAPK1—multiple sclerosis	3.08e-05	0.000407	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCL2—multiple sclerosis	3.07e-05	0.000407	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—POMC—multiple sclerosis	3.07e-05	0.000407	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—MAPK1—multiple sclerosis	3.01e-05	0.000399	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	3.01e-05	0.000398	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	2.94e-05	0.00039	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	2.85e-05	0.000378	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TYK2—multiple sclerosis	2.79e-05	0.00037	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	2.73e-05	0.000362	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL2—multiple sclerosis	2.37e-05	0.000315	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	2.36e-05	0.000313	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL2—multiple sclerosis	2.32e-05	0.000308	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—IL6—multiple sclerosis	2.31e-05	0.000306	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL2—multiple sclerosis	2.27e-05	0.000301	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	2.26e-05	0.000299	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	2.25e-05	0.000298	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MMP9—multiple sclerosis	2.2e-05	0.000291	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—APOE—multiple sclerosis	2.19e-05	0.00029	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	2.15e-05	0.000285	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	2e-05	0.000265	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—STAT3—multiple sclerosis	1.95e-05	0.000259	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	1.91e-05	0.000253	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—POMC—multiple sclerosis	1.88e-05	0.000249	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MYC—multiple sclerosis	1.86e-05	0.000246	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	1.85e-05	0.000245	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	1.82e-05	0.000241	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MYC—multiple sclerosis	1.82e-05	0.000241	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TGFB1—multiple sclerosis	1.81e-05	0.00024	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MAPK1—multiple sclerosis	1.78e-05	0.000235	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MYC—multiple sclerosis	1.78e-05	0.000235	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	1.77e-05	0.000235	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	1.74e-05	0.00023	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ALB—multiple sclerosis	1.72e-05	0.000227	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL6—multiple sclerosis	1.4e-05	0.000185	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL6—multiple sclerosis	1.37e-05	0.000181	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL6—multiple sclerosis	1.34e-05	0.000177	CbGpPWpGaD
